Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GSK2141795

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BACKGROUND With proven single-agent activity and favorable toxicity profile of MEK-1/2 inhibition in advanced leukemia… Expand
Is this relevant?
2018
2018
SummaryBackground We sought to determine the recommended phase II dose (RP2D) and schedule of GSK2141795, an oral pan-AKT kinase… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2018
2018
Aberrant MAPK and PI3K pathway signaling may drive the malignant phenotype in NRAS-mutant and BRAFWT NRASWT metastatic melanoma… Expand
  • table 2
Is this relevant?
2017
2017
2578Background: Aberrant PI3K/AKT signaling in BRAF mutant cancers contributes to resistance to MAPK pathway blockade. We… Expand
Is this relevant?
2016
2016
9511Background: There are few treatment options for patients (pts) with advanced uveal melanoma (UM). MEK inhibition (MEKi) has… Expand
Is this relevant?
2016
2016
Background: Preclinical data demonstrates that activation of RAS/MEK/ERK pathway in basal-like breast cancer (BLBC) leads to… Expand
Is this relevant?
2015
2015
UNLABELLED AKT (a serine/threonine-specific protein kinase) regulates many cellular processes contributing to cytotoxic drug… Expand
  • table 1
  • table 2
  • figure 1
  • figure 1
  • figure 1
Is this relevant?
2011
2011
3003 Background: GSK795 is a potent pan-isoform inhibitor of AKT. The objectives were to define the maximum tolerated dose (MTD… Expand
Is this relevant?
2011
2011
3085 Background: The RAS/RAF/MEK and PI3K/AKT pathways are activated in many human cancers. GSK212 is a potent and selective… Expand
Is this relevant?
2011
2011
5064 Background: GSK795 is a potent, ATP-competitive, pan AKT inhibitor. The purpose of this study was to characterize the… Expand
Is this relevant?